Actym Therapeutics, Inc.

BERKELEY, CA · Founded 2017 · CIK 0001808722 · Biotech · Private

Engineered bacteria platform for delivering cancer immunotherapies

actymthera.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$25M
2 Form D · Jul 2023
39 months since last filing
Contracts
—
No federal contracts on record
Patents
38
9 granted · 29 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$14,106,048
Private capital raisedForm D · SEC$11,238,333
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2459GALECTIN THERAPEUTICS INC—$6.8M
2460Eidos Therapeutics—$26M
2461Expesicor Inc——
2462Actym Therapeutics, Inc.—$25M
2463Verseon Corp—$25M
2464Pharmazz, Inc.—$25M
2465Abzena plc—$4.3M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Benjamin ChenDirector
  • Julie CherringtonDirector
  • Kanad DasDirector
  • James HuangDirector
  • Amit KumarDirector · Promoter
  • Ron MazumderDirector
  • Christopher ThanosDirector · Executive Officer · Promoter

Patents

USPTO · 9 granted of 38

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.